OBJECTIVE: This study was designed to measure the impact of variation in patient follow-up on survival statistics. METHODS: surveillance, epidemiology and end results (SEER) data were used to construct four additional datasets. These datasets simulated scenarios of complete, incomplete, and no follow-up of live patients; and complete and incomplete death ascertainment. Sixty-month observed survival proportions were calculated using the actual SEER data and the four additional datasets. RESULTS: The 60-month observed survival proportion increased from 54.44% under the original SEER dataset to 54.62% under complete ascertainment of deaths with no follow-up among live patients. Under complete death ascertainment, randomly imputing loss to follow-up among 20% of live cases resulted in a 1%-2% decrease in 60-month observed survival for 71 of the 102 SEER site categories. With follow-up limited to ascertainment of deaths, randomly missing 6% of deaths resulted in a 1% or greater increase in 60-month observed survival for 99 SEER site categories. CONCLUSIONS: This study provides evidence to support the importance of complete death ascertainment for producing accurate cancer survival statistics, and that ascertainment of deaths only should generally be sufficient for survival analysis.
OBJECTIVE: This study was designed to measure the impact of variation in patient follow-up on survival statistics. METHODS: surveillance, epidemiology and end results (SEER) data were used to construct four additional datasets. These datasets simulated scenarios of complete, incomplete, and no follow-up of live patients; and complete and incomplete death ascertainment. Sixty-month observed survival proportions were calculated using the actual SEER data and the four additional datasets. RESULTS: The 60-month observed survival proportion increased from 54.44% under the original SEER dataset to 54.62% under complete ascertainment of deaths with no follow-up among live patients. Under complete death ascertainment, randomly imputing loss to follow-up among 20% of live cases resulted in a 1%-2% decrease in 60-month observed survival for 71 of the 102 SEER site categories. With follow-up limited to ascertainment of deaths, randomly missing 6% of deaths resulted in a 1% or greater increase in 60-month observed survival for 99 SEER site categories. CONCLUSIONS: This study provides evidence to support the importance of complete death ascertainment for producing accurate cancer survival statistics, and that ascertainment of deaths only should generally be sufficient for survival analysis.
Authors: Christopher J Johnson; Hannah K Weir; Aliza K Fink; Robert R German; Jack L Finch; Randi K Rycroft; Daixin Yin Journal: Cancer Epidemiol Date: 2012-09-07 Impact factor: 2.984
Authors: Claudia Allemani; Hannah K Weir; Helena Carreira; Rhea Harewood; Devon Spika; Xiao-Si Wang; Finian Bannon; Jane V Ahn; Christopher J Johnson; Audrey Bonaventure; Rafael Marcos-Gragera; Charles Stiller; Gulnar Azevedo e Silva; Wan-Qing Chen; Olufemi J Ogunbiyi; Bernard Rachet; Matthew J Soeberg; Hui You; Tomohiro Matsuda; Magdalena Bielska-Lasota; Hans Storm; Thomas C Tucker; Michel P Coleman Journal: Lancet Date: 2014-11-26 Impact factor: 79.321
Authors: Hannah K Weir; Christopher J Johnson; Angela B Mariotto; Donna Turner; Reda J Wilson; Diane Nishri; Kevin C Ward Journal: J Natl Cancer Inst Monogr Date: 2014-11
Authors: David A Siegel; Jun Li; Helen Ding; Simple D Singh; Jessica B King; Lori A Pollack Journal: Pediatr Blood Cancer Date: 2018-10-23 Impact factor: 3.167
Authors: Grace C Haser; R Michael Tuttle; Henry K Su; Eran E Alon; Donald Bergman; Victor Bernet; Elise Brett; Rhoda Cobin; Eliza H Dewey; Gerard Doherty; Laura L Dos Reis; Jeffrey Harris; Joshua Klopper; Stephanie L Lee; Robert A Levine; Stephen J Lepore; Ilya Likhterov; Mark A Lupo; Josef Machac; Jeffrey I Mechanick; Saral Mehra; Mira Milas; Lisa A Orloff; Gregory Randolph; Tracey A Revenson; Katherine J Roberts; Douglas S Ross; Meghan E Rowe; Robert C Smallridge; David Terris; Ralph P Tufano; Mark L Urken Journal: Endocr Pract Date: 2016-01-22 Impact factor: 3.443
Authors: Ahmedin Jemal; Elizabeth M Ward; Christopher J Johnson; Kathleen A Cronin; Jiemin Ma; Blythe Ryerson; Angela Mariotto; Andrew J Lake; Reda Wilson; Recinda L Sherman; Robert N Anderson; S Jane Henley; Betsy A Kohler; Lynne Penberthy; Eric J Feuer; Hannah K Weir Journal: J Natl Cancer Inst Date: 2017-09-01 Impact factor: 13.506